Therefore, the beta blockers nadolol and propranolol, which are preferentially used clinically for CPVT1, were tested for their efficacy in the treatment of the arrhythmic events observed in the RYR2 Dup 2-c1 iPSC-CMs because they presented with the most prevalent erratic beating frequency. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia 1.